IG
VRTX icon

Ithaka Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Ithaka Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-48,826
Closed -$8.95M – 38
2019
Q2 		$8.95M Sell
48,826
-117
-0.2% -$20.5K 1.36% 27
2019
Q1 		$9M Sell
48,943
-352
-0.7% -$65K 1.43% 26
2018
Q4 		$8.17M Sell
49,295
-1,151
-2% -$199K 1.5% 28
2018
Q3 		$9.72M Sell
50,446
-3,634
-7% -$647K 1.45% 29
2018
Q2 		$9.19M Sell
54,080
-843
-2% -$131K 1.43% 29
2018
Q1 		$8.95M Sell
54,923
-1,400
-2% -$229K 1.5% 27
2017
Q4 		$8.44M Buy
56,323
+22,715
+68% +$3.36M 1.51% 27
2017
Q3 		$5.11M Buy
+33,608
New +$5.06M 0.94% 32

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ithaka Group's VRTX Position: Q3 2019 in Review

Ithaka Group sold out of Vertex Pharmaceuticals (VRTX) in Q3 2019, closing a stake of 48,826 shares — an estimated $8.95M sold.

Ithaka Group first reported a position in VRTX in Q3 2017 and held it in 8 quarters. The position peaked at $9.72M in Q3 2018. 707 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

  • Ithaka Group reported no remaining Vertex Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Ithaka Group sold 48,826 Vertex Pharmaceuticals shares in Q3 2019, an estimated $8.95M.
  • Ithaka Group first reported a position in Vertex Pharmaceuticals in Q3 2017 and held it in 8 quarters.
  • Ithaka Group's Vertex Pharmaceuticals position peaked at $9.72M in Q3 2018.
  • 707 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Ithaka Group's 13F filing for Q3 2019, filed 12 Nov 2019.